Sfoglia per AUTORE
CITARELLA F
Collezione AOU San Luigi di Orbassano

  

Items : 12

MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database. in ESMO open / ESMO Open. 2024 Sep;9(9):103680. doi: 10.1016/j.esmoop.2024.103680. Epub 2024 Aug 29.
2024
ASL Asti
AOU San Luigi di Orbassano

Baldini E; Di Micco C; Banini M; Calvetti L; Leone F; Carta A; Pignataro D; Pozzessere D; Muscolino P; Bria E; Citarella F; Pilotto S; Cortinovis D; Gariazzo E; Pelizzari G; Roca E; Galetta D; Sini C; Delmonte A; Bulotta A; Occhipinti M; Minuti G; Cappuzzo F; Reale ML; Passiglia F; Favaretto A; Malapelle U; Novello S; Pasello G; et alii...

Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2024 May;202:114006. doi: 10.1016/j.ejca.2024.114006. Epub 2024 Mar 11.
2024
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Salerno F; Camerini A; Carta A; Follador A; Berardi R; Toschi L; Zoratto F; Cortinovis DL; Citarella F; Bulotta A; Rastelli F; Adamo V; Guida A; Manzo A; Cecere FL; Belluomini L; Roca E; Pasello G; Cerea G; Montrone M; Delcuratolo MD; Passiglia F; Guaitoli G; Bertolini F; Genova C; Caliman E; Mazzoni F; Siringo M; Gelibter A; et alii...

Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2024 Jan;187:107444. doi: 10.1016/j.lungcan.2023.107444. Epub 2023 Dec 15.
2024
ASL Alessandria
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Malapelle U; Novello S; Garbo E; Agustoni F; Gori S; Grisanti S; Catania C; Buffoni L; Buosi R; Brambilla M; Vavalà T; Scotti V; Carta A; Cerea G; Tiseo M; Delmonte A; Russo A; Cortinovis D; Chiari R; Metro G; Citarella F; Genova C; Roca E; Pilotto S; Bria E; Pelizzari G; Sini C; Galetta D; Bulotta A; et alii...

RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion. in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2023 May;18(5):576-586. doi: 10.1016/j.jtho.2022.12.018. Epub 2023 Jan 13.
2023
AOU San Luigi di Orbassano

Aldea M; Marinello A; Duruisseaux M; Zrafi W; Conci N; Massa G; Metro G; Monnet I; Gomez Iranzo P; Tabbo F; Bria E; Guisier F; Vasseur D; Lindsay CR; Ponce-Aix S; Cousin S; Citarella F; Fallet V; Minatta JN; Eisert A; de Saint Basile H; Audigier-Valette C; Mezquita L; Calles A; Mountzios G; Tagliamento M; Remon Masip J; Raimbourg J; Terrisse S; et alii...

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. in Journal of hematology & oncology / J Hematol Oncol. 2022 Jan 21;15(1):9. doi: 10.1186/s13045-022-01226-2.
2022
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Russo A; Porzio G; Tiseo M; Russano M; Ficorella C; Addeo A; Banna GL; Friedlaender A; Spinelli GP; Metro G; Migliorino MR; Passiglia F; Ricciardi S; Zoratto F; Pecci F; Di Marino P; Mansueto G; De Tursi M; Tuzi A; Gori S; Della Gravara L; Macerelli M; Rastelli F; Chiari R; Gelibter A; Marchetti P; Antonuzzo L; Mazzoni F; et alii...

Post-progression outcomes of NSCLC patients with PD-L1 expression ? 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 May;148:24-35. doi: 10.1016/j.ejca.2021.02.005. Epub 2021 Mar 12.
2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Ficorella C; Addeo A; Friedlaender A; Banna GL; Di Maio M; Spinelli GP; Russo A; Adamo V; De Filippis M; Metro G; Simona C; Natalizio S; Migliorino MR; Landi L; Ricciardi S; Buti S; Minuti G; Nigro O; Cantini L; Bracarda S; Citarella F; Russano M; Filetti M; Zoratto F; Gori S; De Tursi M; Mansueto G; Rocco D; et alii...

Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. in Thoracic cancer / Thorac Cancer. 2021 Mar;12(6):880-889. doi: 10.1111/1759-7714.13852. Epub 2021 Feb 1.
2021
AOU San Luigi di Orbassano

Cortellini A; De Giglio A; Cannita K; Cortinovis DL; Cornelissen R; Baldessari C; Giusti R; D'Argento E; Grossi F; Santoni M; Catino A; Berardi R; Sforza V; Rossi G; Antonuzzo L; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Follador A; Rastelli F; Chiari R; Gravara LD; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; et alii...

Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Jun;150:224-231. doi: 10.1016/j.ejca.2021.03.041. Epub 2021 May 3.
2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Cortellini A; Mazzaschi G; Tiseo M; Pinato DJ; Carmisciano L; Ficorella C; Porzio G; Cannita K; Friedlaender A; Addeo A; Banna GL; Spinelli GP; Adamo V; Russo A; Olmetto E; Metro G; Landi L; Ricciardi S; Migliorino MR; Tabbò F; Minuti G; Tuzi A; Bisonni R; Follador A; Gelibter A; Siringo M; Signorelli D; De Toma A; Garassino MC; et alii...

2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Ficorella C; Porzio G; Cannita K; Addeo A; Banna GL; Friedlaender A; Spinelli GP; Russo A; Adamo V; Metro G; Bironzo P; Passiglia F; Ricciardi S; Migliorino MR; Landi L; Minuti G; Tuzi A; Bordi P; Russano M; Cantini L; Santini D; Citarella F; Zoratto F; Filetti M; Mansueto G; Di Marino P; Grassadonia A; Inno A; et alii...

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ? 50%: a multicenter study with external validation. in Journal for immunotherapy of cancer / J Immunother Cancer. 2020 Oct;8(2):e001403. doi: 10.1136/jitc-2020-001403.
2020
AOU San Luigi di Orbassano

Cortellini A; Ricciuti B; Tiseo M; Bria E; Banna GL; Aerts JG; Barbieri F; Giusti R; Cortinovis DL; Migliorino MR; Catino A; Passiglia F; Torniai M; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Rastelli F; Chiari R; Rocco D; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Grossi F; et alii...

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ? 50% and Their Relationship With Clinical Outcomes. in Clinical lung cancer / Clin Lung Cancer. 2020 Nov;21(6):498-508.e2. doi: 10.1016/j.cllc.2020.06.010. Epub 2020 Jun 21.
2020
AOU San Luigi di Orbassano

Cortellini A; Friedlaender A; Banna GL; Porzio G; Bersanelli M; Cappuzzo F; Aerts JGJV; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Berardi R; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Inno A; Di Marino P; Mansueto G; Zoratto F; et alii...

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ??50. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221. doi: 10.1007/s00262-020-02613-9. Epub 2020 May
2020
AOU San Luigi di Orbassano

Cortellini A; Tiseo M; Banna GL; Cappuzzo F; Aerts JGJV; Barbieri F; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Santini D; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; et alii...

©2024 Tutti i diritti riservati. Biblioteca Virtuale per la Salute - Piemonte